The following are some of today’s top gainers in the pharma/biotech sector.
1. Proteostasis Therapeutics Inc. (PTI)
Gained 161.28% to close Tuesday’s (Dec.12) trading at $6.14.
News: The Company reported positive study results across all three of its cystic fibrosis pipeline programs.
They include data from a 28-day phase II clinical trial of PTI-428 in cystic fibrosis patients receiving Vertex Pharmaceuticals’ Orkambi as their background therapy; initial data from the first five subjects in an ongoing phase I study of PTI-801 in cystic fibrosis patients on Orkambi background therapy and data from a phase I study of PTI-808 in healthy volunteers.
The Company also announced that it has completed a healthy volunteer co-administration study of PTI-428, PTI-808 and PTI-801, with the results indicating that the compounds were generally well-tolerated and could potentially be amenable for once a day dosing.
The Company announced that it intends to offer and sell 7 million shares of its common stock in an underwritten public offering.
2. Vital Therapies Inc. (VTL)
Gained 15.15% to close Tuesday’s trading at $5.70.
News: The Company has been selected for addition to the NASDAQ Biotechnology Index, which will become effective prior to the open of U.S. markets Monday, December 18, 2017.
The Company’s lead investigational product is ELAD, a cell-based therapy for the treatment of acute forms of liver failure.
— Top-line data from phase III trial of ELAD System in subjects with severe alcoholic hepatitis are expected in the third quarter of next year.
As of October 24th, the trial was 79% enrolled based on its target of at least 150 subjects. If it is decided more than 150 subjects are needed to reach 55 deaths under the event-driven design of the trial, the top line data could be delayed.
3. GlycoMimetics Inc. (GLYC)
Gained 14.87% to close Tuesday’s trading at $16.45.
News: The Company reported updated data from…